IDenta Corp. (IDTA) — Análisis de acciones con AI

IDenta Corp. specializes in developing and manufacturing field detection and home diagnostic testing kits for narcotics, explosives, and forensic products. The company serves law enforcement, military, government agencies, and organizations combating illicit drugs and terrorist threats globally.

Descripción general de la empresa

Resumen:

IDenta Corp., based in Israel, develops and supplies narcotics and explosives detection kits, catering to law enforcement and security sectors worldwide. With a focus on field-portable solutions, the company addresses the growing need for rapid on-site testing in homeland security and consumer markets, operating with a negative profit margin of -5.4%.

Acerca de IDTA

IDenta Corp., established in 1997 and headquartered in Jerusalem, Israel, operates within the healthcare sector, specifically focusing on medical diagnostics and research. The company develops, manufactures, and supplies field detection and home diagnostics testing kits for narcotics and explosives, along with forensic products. These offerings cater to the homeland security and consumer markets globally. IDenta's product portfolio includes testing kits for drugs, explosives, and bullet holes, as well as FerroPrint testing products, blood detection kits, precursors of drugs test kits, and portable sniffers. The company's solutions are primarily targeted at law enforcement, military, and government agencies, alongside other organizations involved in combating illicit drugs and terrorist threats. IDenta's business model centers around providing rapid and reliable on-site testing solutions, addressing the increasing demand for efficient detection methods in security-sensitive environments. Despite operating in a niche market, IDenta faces competition from larger and more established players in the diagnostics and security sectors. The company's financial performance reflects the challenges of competing in this space, with a negative profit margin of -5.4%.

Tesis de Inversión

IDenta Corp. presents a focused play on the growing demand for rapid narcotics and explosives detection solutions. The company's specialized product line caters to a niche market within the homeland security and law enforcement sectors. With a market capitalization of $0.00B and a negative P/E ratio of -12.21, the company's valuation reflects its current financial challenges. Key growth catalysts include potential partnerships with government agencies and expansion into new geographic markets. However, investors should be aware of the risks associated with the company's OTC listing and limited financial resources. The company's gross margin of 29.8% indicates potential for profitability improvements through increased sales and operational efficiencies. The beta of 0.48 suggests lower volatility compared to the overall market.

Contexto de la Industria

IDenta Corp. operates in the medical diagnostics and research industry, specifically within the niche market of narcotics and explosives detection. The global market for security screening and detection is driven by increasing security concerns and regulatory requirements. The competitive landscape includes companies like ALID, APPB, CNNA, CPMD, and ENZC, which offer various detection and security solutions. IDenta's focus on field-portable testing kits differentiates it from competitors that may offer more lab-based or stationary solutions. The industry is characterized by technological innovation and evolving threats, requiring companies to continuously adapt and improve their detection capabilities.

Medical - Diagnostics & Research

Healthcare

Oportunidades de crecimiento

Expansion into Emerging Markets: There is a significant opportunity for IDenta to expand its presence in emerging markets where the demand for security and narcotics detection is growing. These markets often have less stringent regulatory environments, allowing for faster market entry. A targeted approach focusing on specific regions with high demand could drive revenue growth. The timeline for this expansion is estimated at 2-3 years, with potential for significant revenue contribution.
Partnerships with Law Enforcement Agencies: Collaborating with law enforcement agencies at the local, national, and international levels can provide IDenta with a stable revenue stream and enhanced credibility. These partnerships can involve supplying testing kits, providing training, and developing customized solutions. Securing long-term contracts with these agencies can ensure consistent demand and market penetration. This opportunity can be realized within the next 1-2 years.
Development of New Testing Technologies: Investing in research and development to create new and improved testing technologies can provide IDenta with a competitive edge. This includes developing more sensitive and accurate detection methods, as well as expanding the range of substances that can be detected. Staying ahead of emerging threats and adapting to evolving security needs is crucial for long-term success. The timeline for developing and commercializing new technologies is estimated at 3-5 years.
Focus on Home Diagnostics Market: Expanding into the home diagnostics market with easy-to-use testing kits for drugs and other substances can tap into a new customer base. This requires developing products that are user-friendly and affordable, as well as establishing distribution channels through retail stores and online platforms. The potential market size for home diagnostics is substantial, offering significant growth opportunities. This expansion can be initiated within the next 1-2 years.
Leveraging Portable Sniffer Technology: IDenta's portable sniffer technology offers a unique advantage in the field of narcotics and explosives detection. By further developing and refining this technology, the company can create more advanced and versatile sniffers that can be used in a variety of settings. This includes developing sniffers that can detect trace amounts of substances and operate in challenging environments. The timeline for enhancing and commercializing this technology is estimated at 2-3 years.

Market Cap of $0.00B reflects the company's small size and limited investor interest.
P/E Ratio of -12.21 indicates that the company is currently not profitable.
Profit Margin of -5.4% highlights the challenges in achieving profitability.
Gross Margin of 29.8% suggests potential for profitability with improved efficiency.
Beta of 0.48 indicates lower volatility compared to the overall market.

Qué hacen

Develops field detection kits for narcotics and explosives.
Manufactures home diagnostic testing kits.
Supplies forensic products for homeland security.
Offers drug testing kits for law enforcement.
Provides explosives detection kits for military use.
Creates bullet-hole testing kits for forensic analysis.
Produces FerroPrint testing products for crime scene investigation.
Develops blood detection kits for forensic applications.

Modelo de Negocio

Sells detection kits to law enforcement agencies.
Supplies testing solutions to military and government organizations.
Distributes forensic products to homeland security markets.
Generates revenue through direct sales and partnerships.

Law enforcement agencies
Military organizations
Government agencies
Homeland security markets

Specialized product line focused on niche market.
Proprietary testing technologies.
Established relationships with law enforcement agencies.
Expertise in narcotics and explosives detection.

Catalizadores

Ongoing: Potential partnerships with law enforcement agencies to supply testing kits.
Ongoing: Expansion into emerging markets with high demand for security solutions.
Upcoming: Development and commercialization of new testing technologies.
Upcoming: Launch of home diagnostics testing kits for drugs and other substances.
Ongoing: Increased adoption of portable sniffer technology in various settings.

Riesgos

Ongoing: Competition from larger and more established players in the diagnostics and security sectors.
Potential: Evolving security threats requiring continuous innovation and adaptation.
Potential: Regulatory changes impacting testing requirements and market access.
Potential: Economic downturn affecting government spending on security and law enforcement.
Ongoing: Limited financial resources and negative profit margin.

Fortalezas

Specialized product line for narcotics and explosives detection.
Proprietary testing technologies.
Established relationships with law enforcement agencies.
Expertise in forensic product development.

Debilidades

Small market capitalization.
Negative profit margin.
Limited financial resources.
OTC listing.

Oportunidades

Expansion into emerging markets.
Partnerships with law enforcement agencies.
Development of new testing technologies.
Focus on home diagnostics market.

Amenazas

Competition from larger and more established players.
Evolving security threats requiring continuous innovation.
Regulatory changes impacting testing requirements.
Economic downturn affecting government spending on security.

Competidores y Pares

Applied DNA Sciences Inc — Focuses on DNA-based security solutions. — (ALID)
AppTech Payments Corp — Provides payment processing solutions, not direct competitor in detection kits. — (APPB)
Canna-Global Acquisition Corp — Focuses on cannabis-related acquisitions, not direct competitor in detection kits. — (CNNA)
Cpm Holdings Inc — Provides process solutions for animal feed and oilseed industries, not direct competitor in detection kits. — (CPMD)
Enzolytics Inc — Focuses on developing therapeutics for infectious diseases, not direct competitor in detection kits. — (ENZC)

Key Metrics

Volume: 0
MoonshotScore: 56/100

Company Profile

CEO: Amichai Glattstein
Headquarters: Jerusalem, IL
Employees: 11
Founded: 2017

AI Insight

AI analysis pending for IDTA

OTC Tier: OTC Other
Disclosure Status: Unknown

Preguntas y respuestas

What does IDenta Corp. do?

IDenta Corp. specializes in the development, manufacture, and supply of field detection and home diagnostic testing kits, primarily focused on narcotics, explosives, and forensic products. The company caters to law enforcement, military, government agencies, and other organizations involved in combating illicit drugs and terrorist threats. Their product line includes testing kits for drugs, explosives, bullet holes, blood detection, and portable sniffers, offering rapid and reliable on-site testing solutions for security-sensitive environments.

What do analysts say about IDTA stock?

As of 2026-03-15, there is limited analyst coverage for IDTA stock due to its OTC listing and small market capitalization. Key valuation metrics such as the negative P/E ratio of -12.21 reflect the company's current lack of profitability. Growth considerations include potential partnerships with government agencies and expansion into emerging markets. Investors should conduct thorough due diligence and consider the risks associated with OTC stocks before investing.

What are the main risks for IDTA?

IDenta Corp. faces several key risks, including competition from larger and more established players in the diagnostics and security sectors. The company's limited financial resources and negative profit margin pose challenges to its long-term sustainability. Evolving security threats require continuous innovation and adaptation, which can be costly and time-consuming. Regulatory changes impacting testing requirements and market access could also negatively affect the company's business. Additionally, the OTC listing carries inherent risks such as low liquidity and greater price volatility.

Is IDTA a good investment right now?

Use the AI score and analyst targets on this page to evaluate IDenta Corp. (IDTA). Our analysis considers fundamentals, technicals, and market sentiment to help you decide.

What is the MoonshotScore for IDTA?

The MoonshotScore is a proprietary 0-100 AI rating that evaluates IDenta Corp. across multiple dimensions including financial health, growth trajectory, and risk factors.

Where can I find IDTA financial statements?

IDenta Corp. financial data including revenue, earnings, and balance sheet metrics are available in the Financials tab on this page, sourced from institutional-grade data providers.

What do analysts say about IDTA?

Analyst consensus targets and ratings for IDenta Corp. are shown in the analysis section. These are aggregated from major Wall Street firms and updated regularly.

How volatile is IDTA stock?

Check the beta and historical price range on this page to assess IDenta Corp.'s volatility relative to the broader market.